

## Pure white cell aplasia (PWCA)

Condition for which IVIg use is in exceptional circumstances only

### Specific Conditions

- Pure white cell aplasia

### Level of Evidence

Nil (Category 4b)

PWCA is a rare syndrome of severe neutropenia and a selective deficiency of granulocyte progenitors. Intravenous immunoglobulin (IVIg) is a reasonable option for patients with immunological PWCA who have failed other therapies (e.g. prednisone or cyclosporine).

**Refer to the current product information sheet for further information.**

**The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.**

### Bibliography

Anderson, D, Ali, K, Blanchette, V, et al 2007, 'Guidelines on the use of intravenous immune globulin for hematologic conditions', *Transfusion Medicine Reviews*, vol. 21, no. 2, suppl. 1, pp. S9–56.

*Generated on: 31 March 2019*